Cargando…
Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive tools
Since the inception of COVID-19 pandemic in December 2019, socio-economic crisis begins to rise globally and SARS-CoV-2 was responsible for this outbreak. With this outbreak, currently, world is in need of effective and safe eradication of COVID-19. Hence, in this study anti-SAR-Co-2 potential of FD...
Autores principales: | Attiq, Naila, Arshad, Uzma, Brogi, Simone, Shafiq, Nusrat, Imtiaz, Fazeelat, Parveen, Shagufta, Rashid, Maryam, Noor, Nadia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479384/ https://www.ncbi.nlm.nih.gov/pubmed/36122771 http://dx.doi.org/10.1016/j.ijbiomac.2022.09.086 |
Ejemplares similares
-
Exploration of phenolic acid derivatives as inhibitors of SARS-CoV-2 main protease and receptor binding domain: potential candidates for anti-SARS-CoV-2 therapy
por: Shafiq, Nusrat, et al.
Publicado: (2023) -
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020) -
Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors
por: Kalhotra, Poonam, et al.
Publicado: (2021) -
Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease
por: Balakrishnan, Vijayakumar, et al.
Publicado: (2020) -
Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
por: Odhar, Hasanain Abdulhameed, et al.
Publicado: (2020)